Group items tagged

Parents are advised to check their children's hair often as cases of head lice infestations are increasing in the UK amid rising temperatures. Superdrug has reported a significant 121 per cent surge in sales of its head lice treatment spray, according to Wales Online. The high-street chemist explains that head lice are particularly prevalent during this time of year as the warmer weather triggers infestations. Head lice and nits (head lice eggs) are very common in young children and are picked up by head-to-head contact. The pesky insects make your head feel itchy. The National Health Service (NHS) recommends taking immediate action against head lice as soon as they are detected. It is not necessary to see a GP for head lice treatment.

In the fast-evolving world of medicine, staying updated with the latest research trends is crucial for healthcare professionals and researchers alike. This helps ensure that patient care is based on the best available evidence and keeps professionals at the forefront of innovations and advancements. Here are six essential tips on how to stay informed about the latest medical research trends. 1. Utilize Trusted Sources The vast amount of information available online can be overwhelming, making it essential to discern credible sources from unreliable ones. Here are some strategies to help: Identify Reputable Journals and Databases: Publications like The New England Journal of Medicine, The Lancet, and JAMA are renowned for their rigorous peer-review processes. Databases like PubMed and Google Scholar are also excellent for accessing a wide range of scientific papers. Check for Peer-Reviewed Articles: Peer review ensures that research has been evaluated by experts in the field, enhancing its credibility. Look for Author Credentials: Research conducted by established experts in the field is more likely to be trustworthy. Evaluate Institutional Affiliations: Research from reputable institutions and organizations often signifies high-quality work.

A Labour Party analysis of NHS trust figures has revealed that around 148,000 people died last year while waiting for treatment in England. This is more than double the figure recorded in 2017/18, which stood at around 60,000 deaths. It even surpasses the mortality rate observed in 2021, during the peak of the Covid pandemic. The Labour Party obtained the data through a freedom of information request sent to every NHS trust in England. Out of the 169 acute and community trusts contacted, 80 responded. The total number of deaths reported by the respondents was 61,396. Extrapolating this figure to all trusts would suggest a total of 148,227 deaths.

Thousands of cancer patients in England are set to gain fast-tracked access to personalised cancer vaccine trials through a new National Health Service(NHS) initiative, the Cancer Vaccine Launch Pad. This groundbreaking service aims to find new life-saving treatments by matching eligible patients with clinical trials across the country. The first patient to receive a personalised vaccine for bowel cancer is Elliot Phebve, a 55-year-old lecturer, treated at University Hospitals Birmingham NHS Foundation Trust. Phebve, diagnosed through a routine health check, underwent surgery and chemotherapy before joining the trial. Sponsored by German biotech company BioNTech SE, the colorectal cancer vaccine trial is one of several taking place across NHS trusts.

"Not possible for pharmacists to check whether prescriptions issued from overseas registered prescribers have been issued in a similarly safe and effective way," the new Minister of State (Department of Health and Social Care) Karin Smyth said during a recent parliamentary written response. At a recent session on Monday, July 29th, at the House of Commons, MP Cat Smith raised an important question directed at the Secretary of State for Health and Social Care. Smith, who represents Lancaster and Wyre, and has been an MP continually since 7 May 2015, inquired about whether the Department of Health and Social Care had conducted a comparative assessment of the UK's stance on prescribing puberty blockers for treating gender incongruence in comparison to other European countries. Responding to the questions, MP Karin Smyth emphasised on the significance of the Cass Review and described it as one of the most thorough examinations conducted across the globe on gender identity services for children and young people.

The Pharmacists' Defence Association (PDA) has welcomed the Chancellor's announcement of a 5.5 percent pay increase for NHS pharmacists. Following the acceptance of the NHS Pay Review Body's (PRB) recommendations, Chancellor Rachel Reeves shared the announcement in a speech to Parliament on 29 July. She confirmed that the pay review bodies' recommendations for health and education for 2024-25 would be fully implemented. Reeves' speech came alongside the release of her audit into public finances, a commitment she made shortly after the recent election. The audit confirms that the recommendations from various PRBs, including those for NHS staff, doctors, dentists, teachers, and other public servants, have been approved and will be acted upon. "That is the right decision for the people who work in and most importantly the people who use our public services…giving hardworking staff the pay rise they deserve while ensuring we can recruit and retain the people we need," Reeves announced.

Customs officials at Mundra port in Gujarat's Kutch district, India, recently seized approximately 6.8 million Tramadol tablets valued at Rs 110 crore (around GBP 10.2 million). The tablets were discovered in two export containers bound for Sierra Leone and Niger in West Africa. Tramadol, an opioid pain medication, was classified as a psychotropic substance under the Narcotic Drugs and Psychotropic Substances Act (NDPS Act) in 2018 and its export is now restricted. This synthetic opioid drug has gained notoriety in recent times as the "Fighter Drug" after it was reported that ISIS fighters used it to stay awake for long hours, said a PIB release on Monday. It is reportedly in high demand in African nations like Nigeria, Ghana, etc. The Mundra Customs seizure is one of the largest seizures of Tramadol since it was notified under the NDPS Act, said the release.

Health and Social Care Secretary, Wes Streeting, visited St Margaret's Hospital in Epping, West Essex, on Thursday (1 August) as part of an ongoing series of planned engagements with NHS trusts across England. Accompanied by NHS Chief Executive, Amanda Pritchard, Streeting observed how NHS staff are using innovative technology to monitor patients at home and prevent unnecessary hospital admissions. He met with staff from the hospital's Care Coordination Centre and the 'hospital at home' hub, which work to reduce unnecessary A&E admissions and facilitate quick and safe discharges home. Before the hospital tour, the health secretary met the trust's falls response team, which uses a specially equipped 'falls car' to assist patients who have fallen at home, preventing A&E visits. Later, Streeting visited the Ross Practice GP surgery in Harlow before holding a town hall event with health leaders in the region.

The government has accepted the Joint Committee on Vaccination and Immunisation's (JCVI) advice for the autumn 2024 COVID-19 vaccination programme. According to the JCVI, the following groups will be eligible for vaccination this autumn: Individuals aged 65 and over Residents of care homes for older adults Those aged 6 months and older in clinical risk groups Minister for Public Health and Prevention, Andrew Gwynne, emphasised the importance of protecting vulnerable populations from COVID-19 and reducing pressure on the NHS. He said: "We are committed to protecting those most vulnerable from COVID and have accepted the independent advice from the JCVI for the autumn 2024 vaccination programme." "I encourage anyone invited for a vaccine to get one as soon as possible to protect yourself and reduce pressure on the NHS during winter, helping to cut waiting times and get the health service back on its feet."

In response to stakeholder feedback, the General Pharmaceutical Council (GPhC) is developing a streamlined, single route to registration that will replace the current multiple-pathway system for overseas pharmacists wishing to practice in Great Britain. This revised approach will include updated standards for the education and training of internationally qualified pharmacists, with all applicants still required to pass a registration assessment. The GPhC's Council intends to streamline the registration pathway, reducing the two-year process to one-year process. This new pathway will encompass both university study and in-practice training. Historically, pharmacists qualified within the European Economic Area (EEA) or European Free Trade Association (EFTA) have been eligible for qualification recognition in Great Britain. While this recognition has been extended until September 2028, the future requirement for EEA-qualified pharmacists to undergo the new registration route remains contingent on forthcoming government decisions. Initially, the GPhC had explored the development of three distinct registration routes for internationally-qualified pharmacists, "however decided to change this proposed approach after considering feedback from stakeholders."

Patients in Ireland with a specific type of lung cancer can now access Merck's TEPMETKO® (tepotinib) as a second-line treatment option, following its approval for reimbursement by the Health Service Executive (HSE). Tepotinib is the first treatment approved in Ireland specifically targeting advanced non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations. Previously, the oral MET inhibitor had been approved in the NHS across England, Wales, Scotland, and Northern Ireland. Patients with advanced NSCLC with METex14 skipping alterations typically have poorer overall survival rates compared to other NSCLC patients. According to Merck, tepotinib has shown consistent and durable antitumor activity in this group, as demonstrated in the VISION study, further cementing its role in clinical practice. Roisin Molloy, Managing Director of Merck Healthcare in Ireland, said: "This is an important step forward for targeted treatments in Ireland and it is fantastic news that the HSE has reimbursed tepotinib."

The British Medical Association (BMA) has urged non-GP partners and contractors, including pharmacists, nurses, and physiotherapists, to support their "Protect Your Patients, Protect Your GP Practice" campaign, which was launched to protest changes to the 2024/25 GP contract. GP contractors and partners across England have strongly opposed the modifications to the GMS contract, leading to an ongoing dispute with the NHS. The BMA highlights that general practice in England currently receives just 6 pence of every NHS pound and an average GMS 'global sum' of £107.57 per registered patient annually. Since 2018/19, CPI erosion to the GMS contract has resulted in a loss of £659 million, or 6.6%. This financial strain has contributed to the closure or merger of over 1,300 practices over the past decade. To address these issues, the BMA is urging all GP contractors and partner members to vote YES in the GPC England non-statutory ballot, which will be open until July 29.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication of semaglutide (Wegovy), authorising its use to reduce the risk of serious heart problems and strokes in adults who are obese or overweight. Semaglutide, a GLP-1 receptor agonist, was previously approved for use in the treatment of obesity and weight management, to be used alongside diet, physical activity and behavioural support. The latest approval establishes it as the first weight loss drug to be prescribed to prevent cardiovascular events, such as cardiovascular death, non-fatal heart attack and non-fatal stroke, in people with established cardiovascular disease and a Body Mass Index (BMI) higher or equal to 27 kg/m2. Novo Nordisk, the manufacturer of Wegovy, received this authorisation on 23 July following compelling evidence from a recent post-approval clinical study involving over 17,600 participants. The study demonstrated that Wegovy, administered at a dose of 2.4 mg once weekly via subcutaneous injection for up to five years, significantly lowers the incidence of major adverse cardiovascular events (MACE) by 20 per cent compared to a placebo.

On World Head and Neck Cancer Day today (27 July), the National Health Service (NHS) has launched a new partnership with the British supermarket chain, Asda to raise awareness of mouth cancer symptoms. As part of this partnership, the NHS will provide vital advice on millions of toothpaste tubes and mouthwash bottles, urging people to consult their GP or dentist if they notice any potential symptoms of mouth cancer. Starting this month, the grocer's own brand of oral hygiene products will feature NHS advice in over 500 Asda stores nationwide. The NHS guidance will be displayed on the packaging, along with a link to more detailed information about mouth and throat cancer on the health service website. Professor Peter Johnson, national clinical director for cancer at NHS England, said: "Early detection of mouth cancer can help save lives and this fantastic new partnership with Asda will be vital in raising awareness of the signs and in supporting the NHS's ambition to diagnose more cancers at an earlier stage.

People are advised to be mindful of medications that may cause sun reactions, and to watch out for dodgy hay fever treatments and fake weight loss pens. For those traveling abroad, the MHRA advises considering the suitability of medicines available to reduce the risk of contracting tropical diseases. Dr Alison Cave, Chief Safety Officer at the MHRA, said: "The summer is an exciting time for many of us, as we take time off to travel and enjoy the warmer weather. "But it is important to understand what this time of year means for our medicines and medical devices, and take the precautions necessary to use products safely and protect ourselves." Watch out for dodgy hay fever treatments Millions of Britons suffer from hay fever symptoms in the summer. The MHRA advises consulting a healthcare professional to find the best treatment for your symptoms. People are also warned to be cautious of medicines advertised as hay fever treatments but not approved for use in the UK, such as Kenalog. This is a prescription-only steroid injection licensed as a medicine for other conditions, but not for the treatment of hay fever.

The Professional Records Standards Body (PRSB), which develops information standards for health and social care records, has appointed Professor Reecha Sofat as the new Chair. She will assume the role at the end of October 2024, succeeding Professor Maureen Baker CBE, who will step down after seven years as Chair of the PRSB. A Clinical Pharmacologist, Professor Sofat has held many leadership roles across the NHS, academia and scientific societies. Professor Sofat is Breckenridge Chair of Clinical Pharmacology at the University of Liverpool. She practices general internal medicine and is also an Associate Director at the British Heart Foundation (BHF) Data Science Centre (DSC) which is led by Health Data Research UK (HDRUK). With a passion for data science and extensive clinical and research insights, Professor Sofat is focused on embedding research into routine health and social care. She said: "I am passionate about using the rich health data that is already collected across NHS and social care to better understand the causes and consequences of disease and improve health outcomes.

The World Health Organization (WHO) issued a warning on Thursday regarding falsified semaglutide medications used for treating type 2 diabetes and obesity in select countries. This WHO Medical Product Alert addresses three falsified batches of the specific brand Ozempic that were detected in Brazil (October 2023), the United Kingdom and Northern Ireland (October 2023), and the United States (December 2023). These falsified semaglutide products were distributed through the regulated supply chain. Novo Nordisk, the genuine manufacturer of Ozempic, confirmed that the three products mentioned in the alert are falsified and were not produced by the company. Healthcare professionals, regulatory authorities and the public are advised to remain vigilant regarding these falsified batches of medicines. Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, urged stakeholders to stop any usage of suspicious medicines and report them to relevant authorities.

On June 3, Synnovis, a pathology laboratory serving several NHS organisations in South East London, was targeted by a ransomware attack. This cyber incident has disrupted vital blood testing services, crucial for a range of medical treatments, and raised significant concerns over data security. NHS England confirmed that a cybercriminal group, Qilin, published data online, claiming it was stolen from Synnovis. The National Crime Agency (NCA) and the National Cyber Security Centre (NCSC) are currently working to authenticate the data and understand its contents. A helpline has been established to address patient concerns, and NHS England urges patients to attend their appointments unless otherwise directed. The attack has rendered some of the NHS's blood testing systems inoperable, causing substantial disruption to medical services in South East London.

Addiction is a complex and multifaceted condition that can significantly impact an individual's physical, emotional, and psychological well-being. Despite the strong desire to overcome addiction, many people struggle to achieve lasting recovery on their own. Professional help is crucial in addiction treatment because it offers specialized knowledge, comprehensive care, and evidence-based approaches tailored to each individual's needs. With the support of trained professionals, individuals are more likely to develop the skills and strategies necessary to achieve and maintain long-term sobriety. Understanding the Nature of Addiction Addiction is often misunderstood as merely a lack of willpower or moral failing. However, it is recognized by the medical community as a chronic disease that affects the brain's reward, motivation, and memory functions. These changes make it exceedingly challenging for individuals to control their substance use, even when facing adverse consequences. Through professional assessment, clinicians can identify the specific nature and extent of the addiction. This involves understanding the types of substances used, frequency, and the presence of co-occurring mental health conditions. Accurate diagnosis is essential for developing a tailored treatment plan that addresses all aspects of the individual's condition. The people behind https://healtreatmentcenters.com/resources/ note that there are many treatment centers and support groups available to help people with addiction. It takes the expertise of professionals to properly diagnose and treat addiction effectively.

Healthcare professionals in the UK are being advised to avoid prescribing the migraine and antiseizure medication topiramate, commonly known by the brand name Topamax, to women and girls unless they fulfil the requirements of a Pregnancy Prevention Programme. This guidance follows new safety measures introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) following a major safety review, which highlighted a potential increased risk of neurodevelopmental disabilities in children exposed to topiramate during pregnancy. The Commission on Human Medicines (CHM) evaluated studies that examined the risks associated with using topiramate during pregnancy. These studies indicated that children born to mothers who took topiramate during pregnancy had an approximately 2 to 3 times higher risk of intellectual disability, autism spectrum disorders, and attention deficit hyperactivity disorder. Based on CHM's recommendations, the MHRA now advises that topiramate should not be prescribed for treating epilepsy during pregnancy unless there is no suitable alternative.